Blood Pressure Medication Recalled for Manufacturing Impurity
Direct Rx is recalling batches of Losartan Potassium/Hydrochlorothiazide tablets due to CGMP deviations with elevated AZIDO impurity levels. The affected product was distributed in Florida.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving manufacturing deviations with elevated AZIDO impurity levels in a prescription pharmaceutical. While no illnesses or injuries have been reported, impurity above acceptable limits in a medication for chronic disease management constitutes a risk-of-harm product, meeting Score 3 criteria.
Plain-English summary
Direct Rx is recalling multiple batches of Losartan Potassium and Hydrochlorothiazide 50/12.5 mg tablets. The affected product is a combination blood pressure medication distributed in Florida under NDC 72189-297-90. Six bottles are involved in this recall.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations identified during manufacturing. Analysis found that AZIDO impurity levels in affected batches exceeded acceptable limits. Elevated impurity levels in pharmaceutical products can compromise product quality and pose risks to patients who depend on consistent medication efficacy.
The affected lots are: 19NO2108 (expires 1/31/25), 19NO2114 (expires 1/31/25), and 22NO2126 (expires 1/31/25). Patients taking this medication should consult their healthcare provider before making any changes to their treatment. No illnesses or injuries have been reported in connection with this recall.
The recalled product
- Product
- LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE)
- Brand
- LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Manufacturer
- Direct Rx
- Category
- Drug — Blood Pressure Medication
- Hazard
- azido-impurity
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lots: 19NO2108 Exp. 1/31/25
- 19NO2114 Exp. 1/31/25
- 22NO2126 Exp. 1/31/25
Distribution
Distributed in 1 state:
- FL
Related recalls
Same brand · LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- HighLosartan Potassium and Hydrochlorothiazide Tablets Recalled for Foreign Plastic Contamination
FDA (Drugs) · 2024-05-22
- HighFDA Recalls Losartan-Hydrochlorothiazide Tablets for Manufacturing Quality Deviations
FDA (Drugs) · 2022-07-06
- HighBlood Pressure Medication Losartan-HCTZ Recalled for Impurity Deviation
FDA (Drugs) · 2022-06-08
- HighLosartan Potassium and Hydrochlorothiazide Recall: Impurity Levels Above Acceptable Limits
FDA (Drugs) · 2022-06-01
- HighBlood pressure medication Losartan and hydrochlorothiazide recalled for elevated azido impurity
FDA (Drugs) · 2022-06-01
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27